- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Lilly's Zyprexa pact with health providers wins approval
January 12, 2012
Bloomberg NewsEli Lilly and Co. has won approval of a $4.5 million settlement with five union health funds and an insurer that alleged improper
marketing of the company's best-selling medication, Zyprexa, raised their costs.
MorePressure rises as Lilly tries squeeze play
January 9, 2012
J.K. WallIndianapolis-based Eli Lilly and Co. is now in the predicament of watching revenue fall as its patents on older products expire,
even as the company needs to spend more money on marketing and research to boost sales of new drugs.
MoreBoston lawsuit claims DES-breast cancer link
January 8, 2012
Associated PressFifty-three women from around the country are suing drug companies, including Eli Lilly and Co., who made and promoted DES
for millions of pregnant women from about 1938 to the early 1970s.
MoreLilly's 2012 earnings forecast misses analyst estimates
January 5, 2012
Bloomberg News, Associated PressIndianapolis-based Eli Lilly and Co. provided a 2012 earnings forecast Thursday morning that missed analyst estimates by a
wide margin, sending shares down.
MoreLilly challenging Biogen patent in London lawsuit
January 5, 2012
Bloomberg NewsEli Lilly and Co. has sued Biogen Idec Inc. in a London court to revoke a European patent on a potential treatment for immune-system
diseases.
MoreLilly losing dominance in diabetes treatment
December 31, 2011
J.K. WallEli Lilly and Co., after more than a decade of setbacks, is counting on diabetes to help it survive a string of patent losses
on other products that have begun to sap the drugmaker's sales.
MorePatent expirations up pressure on Lilly
December 24, 2011
Eli Lilly and Co. lost patent protection on its $5-billion-a-year best-seller Zyprexa in October, plunging the company into
the long-awaited zone of uncertainty that it calls “Years YZ.”
MoreLilly shares rise on possibility for Alzheimer’s drug
December 7, 2011
Bloomberg NewsEli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s
experimental Alzheimer’s drug could double the share price.
MoreTakeda, Lilly may face thousands of suits over Actos claims
December 1, 2011
Bloomberg NewsTakeda Pharmaceutical Co. and marketing co-partner Eli Lilly and Co. may face as many as 10,000 lawsuits in U.S. courts over
allegations that their Actos diabetes drug causes bladder cancer.
MoreDrugmakers, pharmacists at odds
November 28, 2011
J.K. WallIndianapolis-based Eli Lilly and Co. recently rejected CVS Caremark’s demands for big price discounts on its insulins,
leading CVS to kick Lilly’s insulins off its list of recommended drugs.
MoreLilly committed to China despite IP woes
November 21, 2011
J.K. WallIndianapolis-based Eli Lilly and Co. is one of several Western pharmaceutical firms that see China as a linchpin of growth
in coming years, due to patent expirations and a slowdown in government reimbursements for prescription medicines in the U.S.
and European markets.
MorePotential Lilly drug doubles good cholesterol
November 15, 2011
Bloomberg NewsEli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck &
Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.
MorePotential Effient rival shows promise in study
November 14, 2011
Bloomberg NewsA study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could
give the companies entry to a $1 billion-plus market where Eli Lilly already competes.
MoreLilly files suit over flea medication sales from Australia
November 11, 2011
Scott OlsonThe Indianapolis-based pharmaceutical firm claims an Australian veterinary clinic is infringing on its Comfortis flea medication's
trademark by reselling it to U.S. consumers online.
MoreLilly, Amylin agree to end diabetes partnership
November 8, 2011
Bloomberg News, Associated PressAmylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to end a decade-long diabetes partnership to resolve litigation.
Amylin will make an upfront payment of $250 million to Lilly and future revenue-sharing payments of $1.2 billion plus interest.
MoreLilly, Bristol-Myers approved to market wider Erbitux use
November 7, 2011
Bloomberg NewsEli Lilly and Co. and Bristol-Myers Squibb Co. won U.S. approval to expand marketing of the cancer drug Erbitux for late-stage
head and neck tumors.
MoreDrug shortages hit Lilly, Endocyte
November 7, 2011
J.K. WallThe nation’s shortage of certain drugs is threatening to affect research trials being conducted by Eli Lilly and Co.
and Endocyte Inc.
MoreLilly hid Zyprexa's diabetes risks, family’s lawyer argues
November 2, 2011
Bloomberg NewsEli Lilly and Co. hid the diabetes risks of Zyprexa to protect sales, a lawyer for the family of a 20-year-old patient who
died while taking the medicine told a jury in the first case to go to trial over the drug. The attorney asked jurors to award
the family $40 million in compensatory damages.
MoreLilly loses British Supreme Court ruling over gene patent
November 2, 2011
Bloomberg NewsThe British Supreme Court ruled in favor of Human Genome Sciences Inc. in its dispute with Eli Lilly and Co. over the validity
of a patent for a gene sequence that could be used to treat people with immune diseases.
MoreQ&A
October 31, 2011
J.K. WallAs an Eli Lilly and Co. lobbyist in Washington, D.C., Jay Bonitt is hoping the Congressional “super
committee” charged with trimming the federal budget doesn’t turn to the Medicare prescription drug program, known
as Part D, to do so. Bonitt, Lilly's vice president of federal affairs, said the program is under budget and helps spur
drugmakers to further innovation.
MoreLilly fights view that fate hinges on Alzheimer's drug
October 29, 2011
Greg AndrewsAnalysts have eyes on trial data for drug that could be a game-changer for the company.
MoreLilly wins European approval for new use of Alimta
October 28, 2011
J.K. WallIndianapolis-based drugmaker can now market lung cancer drug as a continuation maintenance therapy, potentially boosting sales
after recent loss of patent on bestseller Zyprexa.
MoreZyprexa era comes to an end for Lilly
October 27, 2011
IBJ StaffOn Oct. 24, the U.S. Food and Drug Administration approved the first generic versions of Eli Lilly and Co.’s best-seller,
ending 15 years of highly lucrative sales.
MoreFDA approves first generic versions of Zyprexa
October 24, 2011
IBJ Staff and Associated PressFederal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, which posted sales
of $5.7 billion last year for Indianapolis-based drugmaker Eli Lilly and Co Inc.
MoreLilly: Vendors key after Zyprexa patent loss
October 24, 2011
J.K. WallLilly's patent-loss challenges—the biggest of which takes effect today—will force the company to rely even more
on its 1,300 Indiana vendors.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
It's also across the street from Fogo de Chao and Morton's....
Yep, the haters are trying to make good news bad. I guess it is hard to get people to believe the series is dying when they are gaining new sponsors.
David Copperfield! I remember watching his specials on TV when I was little.
Don't forget this is next to an MMA gym, a pawn shop, and some abandoned spaces.
Good project for Zionsville - A group who has owned the property for many years has waited and worked patiently to bring highest and best use development to a major corridor, and mix that in with the great downtown you have. Win Win. All the Best to Pittman Partners and Zionsville.